IDEAYA Biosciences, Inc. (IDYA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1241668,
    "name": "IDEAYA Biosciences, Inc.",
    "stock_name": "IDEAYA Biosciences, Inc.",
    "full_name": "IDEAYA Biosciences, Inc.",
    "name_url": "stocks-analysis/ideaya-biosciences-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "36.01",
    "chg": 2.32,
    "chgp": "6.89%",
    "dir": 1,
    "prev_price": "33.69",
    "mcapval": "2,049.99",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US45166A1025",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.95 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ideaya-biosciences-inc-1241668-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ideaya-biosciences-inc-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-volatility-3601298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IDEAYABioscienc_technicaldot_3601298.png",
        "date": "2025-10-07 20:45:34",
        "description": "IDEAYA Biosciences, Inc. has recently revised its evaluation amid market fluctuations, with its stock price at $27.49. The company has experienced significant volatility over the past year, with a 52-week high of $32.67 and a low of $13.45. Long-term performance remains strong despite recent challenges."
      },
      {
        "title": "Is IDEAYA Biosciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ideaya-biosciences-inc-technically-bullish-or-bearish-3599297",
        "imagepath": "",
        "date": "2025-10-07 12:23:27",
        "description": "As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong daily moving average signal and a weekly MACD indicating bullish momentum. However, the monthly MACD is only mildly bullish, and the KST shows a bearish signal on that timeframe. The Bollinger Bands present a mixed view, being mildly bullish weekly but mildly bearish monthly. The stock has underperformed the S&P 500 over the past month and year, returning 1.22% compared to the S&P's 4.15% for the month and -8.27% against the S&P's 17.82% for the year, while it has outperformed over the 3-year and 5-year periods. Overall, the strength of the bullish trend is supported by the daily moving averages and weekly MACD, despite some mixed signals from other indicators...."
      },
      {
        "title": "Is IDEAYA Biosciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ideaya-biosciences-inc-technically-bullish-or-bearish-3594024",
        "imagepath": "",
        "date": "2025-10-06 12:13:37",
        "description": "As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The weekly KST is bullish, while the monthly KST is bearish, suggesting some divergence in longer-term momentum. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. The Dow Theory indicates a mildly bullish trend for both weekly and monthly periods. \n\nIn terms of performance, IDEAYA has outperformed the S&P 500 over the past week and month, with returns of 3.02% and 7.30%, compared to the S&P 500's 1.09% and 4.15%, respectively. However, the one-year return of -5.50% lags behind the S&P 500's 17.82%. Overall, the current technical stance is bullish, with moderate strength indicated by the weekly signals...."
      },
      {
        "title": "Is IDEAYA Biosciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ideaya-biosciences-inc-technically-bullish-or-bearish-3592093",
        "imagepath": "",
        "date": "2025-10-05 11:58:44",
        "description": "As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators such as a bullish MACD on the weekly timeframe, bullish moving averages on the daily timeframe, and a bullish OBV on both weekly and monthly timeframes. However, the monthly MACD is only mildly bullish, and the KST shows a bearish signal on the monthly. The Dow Theory indicates a mildly bullish stance on both weekly and monthly timeframes.\n\nIn terms of multi-period returns, IDEAYA has outperformed the S&P 500 over the past week and month, returning 3.02% and 7.30% respectively, while the S&P 500 returned 1.09% and 4.15%. However, it has underperformed over the year with a return of -5.50% compared to the S&P 500's 17.82%. Overall, the stock shows a bullish trend with some mixed signals in longer-term indicators...."
      },
      {
        "title": "Is IDEAYA Biosciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ideaya-biosciences-inc-technically-bullish-or-bearish-3547588",
        "imagepath": "",
        "date": "2025-09-20 19:58:51",
        "description": "As of 8 September 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is bearish, indicating mixed signals across time frames. The daily moving averages are bullish, supporting a positive short-term outlook. However, the monthly Bollinger Bands are mildly bearish, suggesting caution. The stock has shown strong performance over the past three years with a return of 134.95%, significantly outperforming the S&P 500's 70.41% return in the same period. Overall, the current stance is mildly bullish, driven by strong short-term indicators despite some bearish signals in longer time frames...."
      },
      {
        "title": "Is IDEAYA Biosciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ideaya-biosciences-inc-overvalued-or-undervalued-3543914",
        "imagepath": "",
        "date": "2025-09-20 18:32:30",
        "description": "As of 12 November 2020, the valuation grade for IDEAYA Biosciences, Inc. moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 1.86, an EV to EBITDA of -3.40, and a negative ROCE of -108.56%. In comparison to its peers, IDEAYA's EV to EBITDA ratio is significantly worse than Madrigal Pharmaceuticals, Inc. at -30.5845 and Ultragenyx Pharmaceutical, Inc. at -7.2361, both of which also fall under the risky category.\n\nWhile IDEAYA has shown strong returns over the longer term, with a 134.95% return over three years, its recent performance has lagged behind the S&P 500, particularly with a -24.55% return over the past year compared to the index's 17.14%. This underperformance, combined with its high valuation ratios relative to peers, suggests that IDEAYA may not be a favorable invest..."
      },
      {
        "title": "IDEAYA Biosciences Hits Day High with 7.28% Surge Amid Financial Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ideaya-biosciences-hits-day-high-with-728-surge-amid-financial-struggles-3537287",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/IDEAYABioscienc_priceRelatedfactors_3537287.png",
        "date": "2025-09-19 13:39:37",
        "description": "IDEAYA Biosciences, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 2,050 million. Despite a recent increase in stock price, the company has reported negative financial performance for nine consecutive quarters, with significant losses and inefficiencies in capital investment returns."
      }
    ],
    "total": 12,
    "sid": "1241668",
    "stock_news_url": "https://www.marketsmojo.com/news/ideaya-biosciences-inc-1241668"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-07 20:45:34

IDEAYA Biosciences, Inc. has recently revised its evaluation amid market fluctuations, with its stock price at $27.49. The company has experienced significant volatility over the past year, with a 52-week high of $32.67 and a low of $13.45. Long-term performance remains strong despite recent challenges.

Is IDEAYA Biosciences, Inc. technically bullish or bearish?

2025-10-07 12:23:27

As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong daily moving average signal and a weekly MACD indicating bullish momentum. However, the monthly MACD is only mildly bullish, and the KST shows a bearish signal on that timeframe. The Bollinger Bands present a mixed view, being mildly bullish weekly but mildly bearish monthly. The stock has underperformed the S&P 500 over the past month and year, returning 1.22% compared to the S&P's 4.15% for the month and -8.27% against the S&P's 17.82% for the year, while it has outperformed over the 3-year and 5-year periods. Overall, the strength of the bullish trend is supported by the daily moving averages and weekly MACD, despite some mixed signals from other indicators....

Is IDEAYA Biosciences, Inc. technically bullish or bearish?

2025-10-06 12:13:37

As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The weekly KST is bullish, while the monthly KST is bearish, suggesting some divergence in longer-term momentum. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. The Dow Theory indicates a mildly bullish trend for both weekly and monthly periods. In terms of performance, IDEAYA has outperformed the S&P 500 over the past week and month, with returns of 3.02% and 7.30%, compared to the S&P 500's 1.09% and 4.15%, respectively. However, the one-year return of -5.50% lags behind the S&P 500's 17.82%. Overall, the current technical stance is bullish, with moderate strength indicated by the weekly signals....

Is IDEAYA Biosciences, Inc. technically bullish or bearish?

2025-10-05 11:58:44

As of 3 October 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators such as a bullish MACD on the weekly timeframe, bullish moving averages on the daily timeframe, and a bullish OBV on both weekly and monthly timeframes. However, the monthly MACD is only mildly bullish, and the KST shows a bearish signal on the monthly. The Dow Theory indicates a mildly bullish stance on both weekly and monthly timeframes. In terms of multi-period returns, IDEAYA has outperformed the S&P 500 over the past week and month, returning 3.02% and 7.30% respectively, while the S&P 500 returned 1.09% and 4.15%. However, it has underperformed over the year with a return of -5.50% compared to the S&P 500's 17.82%. Overall, the stock shows a bullish trend with some mixed signals in longer-term indicators....

Is IDEAYA Biosciences, Inc. technically bullish or bearish?

2025-09-20 19:58:51

As of 8 September 2025, the technical trend for IDEAYA Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is bearish, indicating mixed signals across time frames. The daily moving averages are bullish, supporting a positive short-term outlook. However, the monthly Bollinger Bands are mildly bearish, suggesting caution. The stock has shown strong performance over the past three years with a return of 134.95%, significantly outperforming the S&P 500's 70.41% return in the same period. Overall, the current stance is mildly bullish, driven by strong short-term indicators despite some bearish signals in longer time frames....

Is IDEAYA Biosciences, Inc. overvalued or undervalued?

2025-09-20 18:32:30

As of 12 November 2020, the valuation grade for IDEAYA Biosciences, Inc. moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 1.86, an EV to EBITDA of -3.40, and a negative ROCE of -108.56%. In comparison to its peers, IDEAYA's EV to EBITDA ratio is significantly worse than Madrigal Pharmaceuticals, Inc. at -30.5845 and Ultragenyx Pharmaceutical, Inc. at -7.2361, both of which also fall under the risky category. While IDEAYA has shown strong returns over the longer term, with a 134.95% return over three years, its recent performance has lagged behind the S&P 500, particularly with a -24.55% return over the past year compared to the index's 17.14%. This underperformance, combined with its high valuation ratios relative to peers, suggests that IDEAYA may not be a favorable invest...

IDEAYA Biosciences Hits Day High with 7.28% Surge Amid Financial Struggles

2025-09-19 13:39:37

IDEAYA Biosciences, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 2,050 million. Despite a recent increase in stock price, the company has reported negative financial performance for nine consecutive quarters, with significant losses and inefficiencies in capital investment returns.

View All News